Full-text?

The full document isn't yet available to us from the patent office.

Abstract

A diagnostic test for preclinical and clinical Alzheimer's disease is based on plasma levels of A² 40 , A² 42 , their ratio, or their rate of entry following administration of antibodies that sequester A². Alterations of any of these parameters from control values identifies preclinical or clinical Alzheimer's disease.


Claims

Information currently unavailable.

Download PDF
Document Preview
Document History
  • Publication: Jul 16, 2008
  • Application: Aug 16, 2002
    EP EP 07024341 A
  • Priority: Aug 16, 2002
    EP EP 02766022 A
  • Priority: Oct 23, 2001
    US US 33498701 P
  • Priority: Aug 17, 2001
    US US 31322101 P

Sign in to the Lens